Ad Hoc Advisory Committee on Peritonitis Management. Peritoneal dialysis-related peritonitis treatment recommendations: 1993 update. PerilDialInt 1993; 13: 14-28.
Ateş K, Nergizoğlu G, Keven K, Effect of fluid and sodium removal on mortality in peritoneal dialysis patients. KidneyInt 2001; 60:767-76.
Baigent, C., Landray, M.J., Reith, C. et al. The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.Lancet.2011;377:2181-2192.
Brown E.A., Davies S.J., Rutherford P., Meeus F., Borras M., WRiegel W., Filho J.C. D., Vonesh E., Van Bree M. Survival of Functionally Anuric Patients on Automated Peritoneal Dialysis: The European APD Outcome Study. JASN November 1, 2003 vol. 14 no. 11 2948-2957.
Brown E.A., Goldberg L.C., Clemenger M., Azadian B. Effective treatment of peritonitis using a once-daily vancomycin-free regime in CAPD and APD (Absiracl). PeritDialInt 1999; 19 (Suppl 1): S30.
Busch S., Schreiber M., Bodnar D., Buchler N., Fuchs J., Jackson-Bey D., Pearl J. The 24-hour D/P ratio is a convenient screen for identifying altered peritoneal transport rates. AdvPeritDial. 1993;9:119-23.
Cho Y, Johnson DW, Badve S, et al. Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials. NephrolDialTransplant 2013; 28:1899-907.
Cho Y,Johnson DW, Craig JC, et al.. Biocompatible dialysis fluids for peritoneal dialysis. CochraneDatabaseSystRev 2014; 3:CD007554.
Cice G, Di Benedetto A,D'Isa S, et al. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial. J Am CollCardiol 2010; 56:1701-8.
Cice G, Ferrara L,Di Benedetto A, et al.. Dilated cardiomyopathy in dialysis patients-beneficial effects of carvedilol: a double-blind, placebo-controlled trial. J AmCollCardiol 2001; 37:407-11.
CiceG,Ferrara L, D'Andrea A, et al. Carvedilol increases two-year survivalin dialysis patients with dilated cardiomyopathy: a prospective, placebo-controlled trial. J Am CollCardiol 2003; 41:1438- 44.
Cockcroft D.W & Gault M.H. Prediction of creatinine clearance from serum creatinine. Nephron 16:31-41, 1976.
de Jager DJ, Grootendorst DC, Jager KJ , et al. Cardiovascular and noncardiovascular mortality among patients starting dialysis. JAMA 2009; 302:1782-9.
Eidemak I, Sorensen HT, Kristensen J. Five months of physical exercise in hemodialysis patients: effects on aerobic capacity, physical function and self-rated health. NephronClinPract 2004; 96:c76-81
Elliott MJ, Zimmerman D, Holden RM. Warfarin anticoagulation in hemodialysis patients: a systematic review of bleeding rates. Am J Kidney Dis 2007; 50(3):433-40.
European Best Practice Guidelines for Haemodialysis (Part 1) Nephrol Dial Transplant (2002) 17 [Suppl 7]
European Best Practice Guidelines for Peritoneal Dialysis Nephrol Dial Transplant 2005;20
European Best Practice Guidelines for the Management of Anaemia in Patients with Chronic Renal Failure Nephrol Dial Transplant 1999;14 [Suppl 5]
European best practice guidelines on haemodialysis (Part 2) Nephrol Dial Transplant (2007) 22 [Suppl 2]:
Fellstrom, B.C., Jardine, A.G., Schmieder, R.E. et al. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis.N Engl J Med. 2009; 360: 1395-1407
Gotch F.A., Keen M.L. Kinetic Modeling in Peritoneal Dialysis. In: Nissenson AR, Fine RN, eds. Clinical Dialysis. 4th ed. New York: McGraw-Hill Medical Publication; 2005:385-420.
Gotch F.A., Lipps B.J., Keen M.L., Panlilio F. Computerized urea kinetic modeling to prescribe and monitor delivered Kt/V (pKt/V, dKt/V) in peritoneal dialysis. Fresenius Randomized Dialysis Prescriptions and Clinical Outcome Study (RDP/CO). AdvPeritDial. 1996;12:43-5.
Hakim R.M., Lazarus M.: Initiation of dialysis. AmSocNephrol 6:1319-1328, 1995.
Hallan S., Asberg A., Lindberg M., Johnsen H. Validation of the Modification of Diet in Renal Disease formula for estimating GFR with special emphasis on calibration of the serum creatinine assay. Am J KidneyDis; 44(1): 84-93, 2004 Jul.
Hansson J.H. and Watnick S. Update on Peritoneal Dialysis: Core Curriculum 2016. Am J KidneyDis. 2016;67(1):151-164.
Heiwe S, Jacobson SH Exercise training for adults with chronic kidney disease. CochraneDatabaseSystRev 2011:CD00323
Himmele R., Jensen L., Fenn D., Ho C.H., Sawin D.A., Diaz-Buxo J.A. A new neutral pH low GDP peritoneal dialysis fluid. PeritDialInt. 2012;32:444-452.
Ikiller T.A., Greene J.H., Wingard R.L., Parker R.A., Hakim R.M.: Spontaneous dietary protein intake during progression of chronic renal failure. 1 AmSocNephrol 6:1386-1391, 1995.
Ito Y, Mizuno M, Suzuki Y, et al. Long-term effects of spironolactone in peritoneal dialysis patients. J Am SocNephrol 2014; 25:1094-102.
Jager KJ, Merkus MP, Boeschoten EW, et al.. Dialysis in the Netherlands: the clinical condition of new patients put into a European perspective. NECOSAD Study Group. Netherlands Cooperative Study on the Adequacy of Dialysis phase 1. NephrolDialTransplant 1999; 14:2438- 44.
Johnson D.W., Brown F.G., Clarke M. et al. The effects of biocompatible compared with standard peritoneal dialysis solutions on peritonitis microbiology, treatment, and outcomes: the balANZ trial. PeritDialInt. 2012; 32(5):497-506.
Johnson D.W., Hawley C.M., McDonald S.P. Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. NephrolDialTransplant. 2010;25(6):1973-1979.
KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease Kidney Int Supplements 2012; Vol 2, Issue 4, August (2)
KDIGO Clinical Practice Guideline for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Kidney Int 2009 Vol 76, Suppl 113